% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kersting:276914,
author = {J. Kersting$^*$ and A. Ranft$^*$ and V. Bhadri and B.
Brichard and S. Collaud and S. Cyprová and H. Eich and T.
Ek and H. Gelderblom and J. Hardes$^*$ and L. Haveman and W.
Hartmann and P. Hauser and P. Heesen and H. Jürgens and J.
Kanerva and T. Kühne and A. Raciborska and J. Rascon and V.
Rechl and A. Streitbürger$^*$ and B. Timmermann$^*$ and Y.
Uhlenbruch and U. Dirksen$^*$},
title = {{E}ffect of {R}adiotherapy {D}ose on {O}utcome in
{N}onmetastatic {E}wing {S}arcoma.},
journal = {Advances in radiation oncology},
volume = {8},
number = {4},
issn = {2452-1094},
address = {Amsterdam},
publisher = {Elsevier},
reportid = {DKFZ-2023-01207},
pages = {101269},
year = {2023},
abstract = {Radiation therapy (RT) is an integral part of Ewing sarcoma
(EwS) therapy. The Ewing 2008 protocol recommended RT doses
ranging from 45 to 54 Gy. However, some patients received
other doses of RT. We analyzed the effect of different RT
doses on event-free survival (EFS) and overall survival (OS)
in patients with EwS.The Ewing 2008 database included 528
RT-admitted patients with nonmetastatic EwS. Recommended
multimodal therapy consisted of multiagent chemotherapy and
local treatment consisting of surgery $(S\&RT$ group) and/or
RT (RT group). EFS and OS were analyzed with uni- and
multivariable Cox regression models including known
prognostic factors such as age, sex, tumor volume, surgical
margins, and histologic $response.S\&RT$ was performed in
332 patients $(62.9\%),$ and 145 patients $(27.5\%)$
received definitive RT. Standard dose ≤ 53 Gy (d1) was
admitted in $57.8\%,$ high dose of 54 to 58 Gy (d2) in
$35.5\%,$ and very high dose ≥ 59 Gy (d3) in $6.6\%$ of
patients. In the RT group, RT dose was d1 in $11.7\%,$ d2 in
$44.1\%,$ and d3 in $44.1\%$ of patients. Three-year EFS in
the $S\&RT$ group was $76.6\%$ for d1, $73.7\%$ for d2, and
$68.2\%$ for d3 (P = .42) and in the RT group $52.9\%,$
$62.5\%,$ and $70.3\%$ (P = .63), respectively.
Multivariable Cox regression revealed age ≥ 15 years
(hazard ratio [HR], 2.68; $95\%$ confidence interval [CI],
1.63-4.38) and nonradical margins (HR, 1.76; $95\%$ CI,
1.05-2.93) for the $S\&RT$ group (sex, P = .96; histologic
response, P = .07; tumor volume, P = .50; dose, P = .10) and
large tumor volume (HR, 2.20; $95\%$ CI, 1.21-4.0) for the
RT group as independent factors (dose, P = .15; age, P =
.08; sex, P = .40).In the combined local therapy modality
group, treatment with higher RT dose had an effect on EFS,
whereas higher dose of radiation when treated with
definitive RT was associated with an increased OS.
Indications for selection biases for dosage were found.
Upcoming trials will assess the value of different RT doses
in a randomized manner to control for potential selection
bias.},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37334316},
pmc = {pmc:PMC10276219},
doi = {10.1016/j.adro.2023.101269},
url = {https://inrepo02.dkfz.de/record/276914},
}